Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...
Major trial boost: Phase 2 data showed INBRX-106 plus Keytruda doubled response rates in high PD-L1 head and neck cancer patients. Deeper tumor shrinkage: Most responders in the combo arm had over 50% ...
(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...
Keytruda plus chemotherapy did not negatively affect health-related quality of life in cervical cancer patients, regardless of Avastin addition. The KEYNOTE-826 trial involved 587 patients, assessing ...
Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo. Keytruda (pembrolizumab) in the ...
Erasca (ERAS) on Monday announced a clinical trial collaboration and supply agreement (CTCSA) with Merck (MRK), known as MSD ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
As biopharma industry watchers wait to see whether Keytruda will hit its goal as a postsurgery treatment in early lung cancer patients with high tumor expressions of the PD-L1 biomarker, Merck & Co.
Following the paper trail to Guatemala to uncover what records can’t reveal about access to Keytruda
I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results